Reckitt Benckiser Share Discussion Threads

[minerve] 25/2/2019 14:41

Thanks Essential. I'll take a look. Hope the markets are being good to you in the run-up to Brexit.

[essentialinvestor] 25/2/2019 14:31

M, the conference call is worth a listen. It's well over 2hrs though.
Quicker to read the transcript on SA.
Although a very different business, the Kraft write down has focused some
renewed attention on the price RB paid for MJ. That would be my take.

[minerve] 25/2/2019 14:25

This is starting to looking interesting folks.

[essentialinvestor] 22/2/2019 15:10

Doubled up at 58.74, whether that's a decent price I'm less sure.
We did dip under 56 recently. Still a small position for me.

The recent conference call transcript is on SA for anyone interested.
Had a read of some of it.

Main short term concern is GBP is going to leap on any BREXIT deal.

If you think we are leaving with No deal then you should perhaps be
buying the overseas earners by the bucket load. Don't see that happening myself.

[essentialinvestor] 22/2/2019 14:14

Just done the same.

KHC around 20% Down pre market. Very different company profile to RB,
but expected some ripples here on that news, as with ULVR.

[philanderer] 22/2/2019 14:06

A small buy for me at 5882p

[essentialinvestor] 22/2/2019 10:53

The KHC shocker weighing on consumer products today.

I've seen a TA view on RB. that gave 53 as a target price.

[dr biotech] 22/2/2019 08:53

Boost from results seems short lived. Been the case with a few of mine recently

[essentialinvestor] 21/2/2019 11:35

Had another small amount earlier. Might pay to wait here for lower levels.

[essentialinvestor] 20/2/2019 14:26

Right, I've just joined you bunch of optimists ;.
Prefer ULVR, think this is a better buy under 55, but who knows.

[philanderer] 20/2/2019 12:03

20th feb RBC 'underperform' tp 5300p up from 5100p

[philanderer] 19/2/2019 10:43

😊

---

AJ Bell: spin-off tops questions for new Reckitt boss


A potential sale or spin-off of Reckitt Benckiser’s (RB) health and hygiene home division is likely to be among the decisions facing the successor to chief executive Rakesh Kapoor, who is retiring at the send of the year.

The separation of the health and hygiene home business will be completed in 2020 and the division contributed a better-than-expected fourth quarter performance, which sent the shares 4.6% higher to £62.96 yesterday.

AJ Bell analyst Russ Mould said while Kapoor’s final 12 months in charge ‘aren’t likely to be knock-out, they should be steady, with margins held flat and growth between 3% and 4%’.

‘Questions for Kapoor’s replacement are likely to include whether to prioritise revenue growth over profitability and whether separating out health and hygiene home should be the precursor to a more formal and permanent split through a sale or spin-off,’ he said.

[toffeeman] 19/2/2019 09:59

I always say - what would be the point of brokers if they all had the same estimates :)?

[philanderer] 19/2/2019 09:58

RB.updated.. all over the place ;-)

19th feb Deutsche buy tp 8000p
19th feb UBS neutral tp 6400p
18th feb Liberum buy tp 7300p
18th feb Investec sell tp 5600p


18th feb ++++ Full Year Results ++++

[philanderer] 19/2/2019 09:57

EI , quality company , finger on the pulse ;-)

Interesting..

'Fast fashion: 'Penny on a garment' to drive clothes recycling'

[essentialinvestor] 18/2/2019 13:31

Phil, ABF looks interesting if you see some BREXIT resolution as likely.

[philanderer] 18/2/2019 13:24

18th feb Investec sell tp 5600p

reiterates

[philanderer] 18/2/2019 12:23

Lot of it about. Get well soon. 16 deg C forecast for the end of the week :-)


Fair bit of comment here:

[essentialinvestor] 18/2/2019 12:19

Not atm Phil. Might need some of their cold and flu today,
that's probably GSK though.

[philanderer] 18/2/2019 12:17

Afternoon EI , can't see much wrong . Are you still holding ?

[essentialinvestor] 18/2/2019 12:15

Phil, looks a decent set of results.

[philanderer] 18/2/2019 12:08

Had a few this morning. Luck to all.


Comment:

George Salmon, analyst at Hargreaves Lansdown, said: “An improved performance from the recently acquired infant nutrition business has helped Reckitt’s results come in slightly ahead of expectations. However, a strong showing in North America is masking continued problems in the key Chinese market, which is still hamstrung by weaker demographics and ongoing supply chain issues.

On Kapoor's retirment after eight years at the helm, he said whoever takes over "will be inheriting an attractive business, but after incurring the disruption of a cyber attack and the infant nutrition business still causing a few sleepless nights, there are teething problems to overcome".

"With Reckitt’s divisions clearly divided into Health and Hygiene and Home, we wouldn’t rule out the new CEO following in the footsteps of GSK and overseeing a break-up of the business. Whatever lies ahead, it promises to be an intriguing year for the group.”





Lioberum reiterates 'buy'... tp 7300p

[mozy123] 18/2/2019 10:51

Interesting indeed EI.

[essentialinvestor] 24/1/2019 13:15

Next update may be interesting!.

[dr biotech] 24/1/2019 10:37

I'm thinking about it. Getting a new CEO on a reasonable pay packet will save £50m - performance vs peers over the last couple of years has been dismal. Not really sure that the MJ acquisition was value enhancing.

The share price is back where I bought it - thats better than others(!) but not exactly worthwhile